Agenus Inc (NASDAQ:AGEN) – Research analysts at William Blair reduced their Q3 2019 earnings per share estimates for shares of Agenus in a report released on Wednesday, August 14th. William Blair analyst M. Phipps now expects that the biotechnology company will earn ($0.40) per share for the quarter, down from their previous forecast of ($0.38). William Blair also issued estimates for Agenus’ Q4 2019 earnings at ($0.47) EPS, FY2019 earnings at ($1.12) EPS, Q1 2020 earnings at ($0.48) EPS, Q2 2020 earnings at ($0.49) EPS, Q3 2020 earnings at ($0.49) EPS, Q4 2020 earnings at ($0.50) EPS, FY2020 earnings at ($1.96) EPS, FY2021 earnings at ($1.96) EPS, FY2022 earnings at ($2.06) EPS and FY2023 earnings at ($1.99) EPS.

Separately, BidaskClub lowered Agenus from a “sell” rating to a “strong sell” rating in a research note on Friday, July 26th.

Shares of AGEN opened at $2.86 on Monday. The firm has a market cap of $385.84 million, a PE ratio of -1.99 and a beta of 1.86. The firm has a fifty day simple moving average of $2.57 and a two-hundred day simple moving average of $2.82. Agenus has a 1-year low of $1.54 and a 1-year high of $3.88.

Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.05). The business had revenue of $15.72 million for the quarter, compared to analyst estimates of $5.37 million.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of Agenus by 11.0% in the 2nd quarter. BlackRock Inc. now owns 9,294,627 shares of the biotechnology company’s stock worth $27,884,000 after purchasing an additional 919,105 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Agenus by 16.7% in the 2nd quarter. Vanguard Group Inc. now owns 5,540,211 shares of the biotechnology company’s stock worth $16,620,000 after purchasing an additional 793,180 shares in the last quarter. Oracle Investment Management Inc. increased its stake in shares of Agenus by 3.7% in the 2nd quarter. Oracle Investment Management Inc. now owns 1,408,918 shares of the biotechnology company’s stock worth $4,227,000 after purchasing an additional 50,000 shares in the last quarter. Northern Trust Corp increased its stake in shares of Agenus by 0.9% in the 2nd quarter. Northern Trust Corp now owns 1,167,016 shares of the biotechnology company’s stock worth $3,501,000 after purchasing an additional 10,663 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Agenus by 34.1% in the 4th quarter. Geode Capital Management LLC now owns 1,062,200 shares of the biotechnology company’s stock worth $2,528,000 after purchasing an additional 269,890 shares in the last quarter. Hedge funds and other institutional investors own 34.31% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Featured Article: No Load Funds

Earnings History and Estimates for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.